Form 4: Celldex Therapeutics SVP Exercises Options and Sells Shares
SEC Form 4
Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics, exercised stock options and sold shares on June 3, 2024.
Summary
- On June 3, 2024, Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics, exercised incentive stock options to acquire 8,006 shares of common stock at a price of $10.38 per share.
- Simultaneously, Jimenez sold 8,006 shares of common stock at a price of $33.6001 per share.
- Following these transactions, Jimenez directly owns 25,924 shares of Celldex Therapeutics common stock and 27,994 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. The sentiment is neither positive nor negative as it simply reflects the execution of pre-existing stock option plans and subsequent sale of shares.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership, but it's unlikely to be significant given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 06/18/2021 | 25% of incentive stock options vested |
| 06/03/2024 | Date of transaction: Exercise of stock options and sale of shares |
| 06/05/2024 | Date of signature on the Form 4 filing |
| 06/18/2030 | Expiration date of incentive stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.